Abstract
Therapeutic proteins have become a very valuable addition to the repertoire of drugs to treat patients with severe diseases. Therapeutic proteins differ in many aspects from classical, small molecule drugs. They differ, for example, in molecular size, uniformity of the active, production, purification, contaminations, side effects, stability, formulation, regulatory aspects, and price.
This chapter describes basic elements of the selection, design, cloning and production of biopharmaceuticals. The importance of the expression host in relation to specific post-translational modifications, such as the formation of disulfide bridges and glycosylation, is discussed. And finally, we describe the molecular biological aspects of the design and production of (humanized) monoclonal antibodies in cell culture.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSuggested Reading
Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2(1):52–62
EvaluatePharma® World Preview 2017 (2017) Outlook to 2022. http://info.evaluategroup.com/rs/607-YGS-364/images/WP17.pdf. Accessed 3 Apr 2018.
GAciarz A, Khatri NK, Velez-Superbie ML, Saaranen MJ, Uchida Y, Keshavarz-Moore E, Ruddock LW (2017) Efficient soluble expression of disulfide bonded proteins in the cytoplasm of Escherichia coli in fed batch fermentations on chemically defined minimal media. Microbio Cell Fact 16:108
Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J (2005) SDR grafting-a new approach to antibody humanization. Methods 36(1):2–34
Kim JY, kim Y-G, Lee GM (2012) CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol 93:917–930
Kircher M, Kelso J (2010) High-throughput DNA sequencing-concepts and limitations. Bioessays 32(6):524–536
Kunert R, Reinhart D (2016) Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol 100:3451–3461
Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7(1):21–39
Lodish H, Berk A, Kaiser CA, Krieger M, Scott MP (2007) Molecular cell biology, 6th edn. WH. Freeman & CO, New York
Nothaft H, Szymanski CM (2010) Protein glycosylation in bacteria: sweeter than ever. Nat Rev Microbiol 8(11):765–778
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9(3):203–214
Rosano GL, Ceccarelli EA (2014) Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 5(172):1–17
Strohl WR, Knight DM (2009) Discovery and development of biopharmaceuticals: current issues. Curr Opin Biotechnol 20(6):668–672
Wells EA, Robinson AS (2017) Cellular engineering fro therapeutic protein production: product quality, host modification, and process improvement. Biotechnol J 12:16001015, 1–16001015,12
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Oosting, R.S. (2019). Molecular Biotechnology: From DNA Sequence to Therapeutic Protein. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-030-00710-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-00710-2_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-00709-6
Online ISBN: 978-3-030-00710-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)